Lasilactone® (Furosemide + Spironolactone)
Disclaimer
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
This drug commentary is intended for educational and professional reference purposes and does not replace the current approved Egyptian package leaflet, Summary of Product Characteristics (SmPC), prescribing information, or individualized clinical judgment. Because formulations, manufacturers, indications, contraindications, and regulatory information may differ between countries and may change over time, the product actually dispensed should always be checked against its current package labeling.
1. Summary
Lasilactone® is a fixed-dose oral diuretic combination containing spironolactone, a potassium-sparing mineralocorticoid receptor antagonist (aldosterone antagonist), and furosemide, a potent loop diuretic.
The combination produces complementary diuresis and natriuresis:
- Furosemide produces powerful inhibition of sodium and chloride reabsorption in the thick ascending limb of the loop of Henle.
- Spironolactone antagonizes aldosterone in the distal nephron, reducing sodium reabsorption and limiting potassium loss.
This combination is particularly useful when edema or fluid retention is associated with secondary hyperaldosteronism, especially in conditions such as cirrhosis with ascites and congestive heart failure.
The currently reported Egyptian-market presentations are:
- Lasilactone 50/20 mg, 30 film-coated tablets
- Lasilactone 100/20 mg, 30 film-coated tablets
The numerical strength convention is important: 50/20 mg means spironolactone 50 mg + furosemide 20 mg, whereas 100/20 mg means spironolactone 100 mg + furosemide 20 mg.
The combination requires careful monitoring because the two components exert partially opposing effects on potassium balance: furosemide tends to cause potassium loss, whereas spironolactone tends to increase serum potassium.
2. Brand Name
Lasilactone®
The product has historically been marketed in different countries and formulations under closely related names such as Lasilacton/Lasilactone, and the exact formulation, pharmaceutical form, pack size, and regulatory status may vary by market.
For the Egyptian market information supplied:
- Lasilactone 100/20 mg 30 F.C. tablets
- Lasilactone 50/20 mg 30 tablets
Current Egyptian pharmacy listings identify the manufacturer as SANOFI.
3. Category
Therapeutic category: Combination diuretic.
Pharmacological category:
- Loop diuretic + potassium-sparing diuretic
- High-ceiling diuretic + aldosterone antagonist
- Fixed-dose combination diuretic
ATC classification: C03EB01 — furosemide and potassium-sparing agents.
The combination is pharmacologically rational because furosemide promotes substantial natriuresis and kaliuresis, whereas spironolactone antagonizes aldosterone-mediated sodium retention and potassium wasting.
4. Active Ingredients
Lasilactone 50/20 mg
Each film-coated tablet contains:
- Spironolactone 50 mg
- Furosemide 20 mg
Lasilactone 100/20 mg
Each film-coated tablet contains:
- Spironolactone 100 mg
- Furosemide 20 mg
The older Egyptian leaflet supplied with the product describes spironolactone as being present in micronized form.
5. Pharmaceutical Form & Strength
Pharmaceutical form: Oral film-coated tablet.
Current Egyptian-market presentations reported:
| Product | Spironolactone | Furosemide | Pack |
|---|---|---|---|
| Lasilactone 50/20 mg | 50 mg | 20 mg | 30 tablets |
| Lasilactone 100/20 mg | 100 mg | 20 mg | 30 tablets |
The older leaflet supplied with the product stated a presentation of 10 film-coated tablets. This should be regarded as historical packaging information and should not override the current Egyptian-market presentation of 30 tablets.
6. Manufacturer & Marketing Authorization Holder
Egyptian market
The current Egyptian-market listings supplied identify:
Manufacturer: Sanofi.
The historical Egyptian leaflet supplied with the product states:
Produced by:
Sanofi-Aventis Egypt S.A.E.
Under licence of:
Sanofi-Aventis / Germany
A current publicly accessible Egyptian regulatory document sufficient to independently verify the exact present-day Egyptian Marketing Authorization Holder (MAH) was not identified in the sources reviewed.
Therefore, the most accurate wording is:
Manufacturer / local production: Sanofi / Sanofi-Aventis Egypt S.A.E. according to the historical Egyptian leaflet and current market listings.
Marketing Authorization Holder: Sanofi-affiliated entity; the exact current Egyptian MAH should be confirmed from the current Egyptian regulatory registration/package labeling rather than inferred from older documentation.
For comparison, historical UK documentation for Lasilactone identifies Sanofi as the Marketing Authorisation Holder, but this does not automatically establish the Egyptian MAH.
7. Mechanism of Action
A. Furosemide
Furosemide is a loop diuretic.
It inhibits the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) in the luminal membrane of the thick ascending limb of the loop of Henle.
This produces:
- Marked natriuresis
- Increased chloride excretion
- Increased water excretion
- Increased potassium excretion
- Increased calcium excretion
- Increased magnesium excretion
Because the thick ascending limb normally generates a hypertonic medullary interstitium, inhibition of this transporter also reduces the kidney's ability to concentrate urine.
Furosemide therefore produces a rapid and powerful diuretic effect.
B. Spironolactone
Spironolactone is a competitive antagonist of the mineralocorticoid receptor.
Aldosterone normally increases:
- Sodium reabsorption
- ENaC activity
- Na⁺/K⁺-ATPase activity
- Potassium secretion
- Hydrogen-ion secretion
By antagonizing aldosterone, spironolactone:
- Reduces sodium reabsorption
- Promotes sodium and water excretion
- Reduces potassium and hydrogen-ion secretion
- Has a potassium-sparing effect
Its action is particularly important in states of secondary hyperaldosteronism, such as cirrhosis with ascites and certain forms of heart failure.
C. Why the combination is useful
The two drugs act at different sites in the nephron and address different mechanisms of sodium retention.
Furosemide provides strong natriuresis, while spironolactone counteracts aldosterone-mediated distal sodium retention and helps reduce the potassium loss that can accompany loop diuretic therapy.
However, the combination does not guarantee normal potassium levels. Hyperkalemia can still occur, especially with renal impairment or concomitant renin-angiotensin-aldosterone system blockade.
8. Spectrum of Activity
Not applicable.
Lasilactone is not an antimicrobial drug and therefore has no antibacterial, antiviral, antifungal, or antiparasitic spectrum.
9. Pharmacokinetics
Furosemide
Furosemide is administered orally in this product.
After oral administration, diuresis generally begins within approximately 1 hour, with peak diuretic effect during the first 1–2 hours and a duration commonly around 6–8 hours, although clinical response varies.
Oral bioavailability is variable and is lower and more unpredictable than intravenous administration.
Furosemide is extensively bound to plasma proteins, primarily albumin.
It is largely eliminated through renal tubular secretion and metabolism to furosemide glucuronide.
The terminal plasma half-life is approximately 2 hours, although the pharmacodynamic effect lasts longer than the plasma half-life.
Absorption may be altered in patients with edema and severe heart failure.
Spironolactone
Spironolactone is rapidly and extensively metabolized after oral administration.
Important active metabolites include:
- Canrenone
- 7-alpha-thiomethylspironolactone
- 6-beta-hydroxy-7-alpha-thiomethylspironolactone
The parent drug has a short plasma half-life of approximately 1.4 hours, while its active metabolites have considerably longer half-lives.
Current prescribing information reports mean half-lives of approximately:
- Canrenone: 16.5 hours
- 7-alpha-thiomethylspironolactone: 13.8 hours
- 6-beta-hydroxy-7-alpha-thiomethylspironolactone: 15 hours
Food substantially increases spironolactone exposure; therefore, patients should take it consistently with respect to meals rather than changing repeatedly between fed and fasting administration.
Spironolactone and its metabolites are highly protein bound.
Onset of clinical effect
Furosemide acts rapidly.
Spironolactone has a slower pharmacodynamic effect because it acts through modulation of gene transcription and downstream mineralocorticoid-responsive proteins. The maximum therapeutic response may require approximately 2–3 days.
Therefore, increasing spironolactone doses too rapidly based solely on the first day's diuresis may be inappropriate.
10. Indications
The precise approved indications depend on the current Egyptian registration and labeling. Pharmacologically and clinically, the combination is used for conditions associated with clinically significant fluid retention where combined loop and aldosterone-antagonist therapy is appropriate.
The historical Lasilactone leaflet supplied states indications including:
A. Edema
Fluid accumulation in:
- Peripheral tissues
- Other tissues
- Body cavities
particularly when associated with conditions responsive to diuretic treatment.
B. Ascites
Particularly:
- Ascites associated with liver disease
- Cirrhosis-associated ascites
- Ascites associated with secondary hyperaldosteronism
C. Heart failure
Edema associated with congestive heart failure may be treated with diuretic therapy.
D. Cor pulmonale
The old leaflet specifically lists edema associated with cor pulmonale.
E. Nephrotic syndrome
The historical leaflet also lists edema associated with nephrotic syndrome.
F. Hyperaldosteronism-associated fluid retention
The historical indication includes edema or ascites associated with excessive aldosterone levels that has not responded adequately to previous diuretic therapy.
Important clinical qualification
The presence of an indication for the individual components does not automatically mean that the fixed-dose Lasilactone combination is the preferred formulation for every patient.
Current clinical practice generally individualizes the dose of spironolactone and furosemide according to:
- Underlying disease
- Degree of fluid retention
- Blood pressure
- Renal function
- Serum potassium
- Serum sodium
- Weight response
- Urine output
- Other concomitant medications
11. Administration
Lasilactone is administered orally.
The tablet should be swallowed with an adequate amount of fluid.
Because furosemide produces diuresis, administration late in the evening may interfere with sleep because of increased urination.
The historical leaflet therefore recommended administration preferably with breakfast or lunch and advised against evening administration, particularly at the beginning of treatment.
This remains a reasonable practical principle when clinically appropriate.
Food
Because spironolactone exposure is affected substantially by food, administration should be kept consistent with regard to meals.
Therefore, rather than focusing solely on "with food" versus "without food," the important practical point is:
Take the medicine consistently in relation to meals.
Duration
Treatment duration depends on the underlying disease and the patient's response.
Lasilactone should not be continued indefinitely without periodic reassessment of:
- Volume status
- Blood pressure
- Renal function
- Serum potassium
- Serum sodium
- Other relevant electrolytes
12. Dosage
Important update regarding the historical leaflet
The supplied historical leaflet states:
For the first 3–6 days, 1 tablet up to 4 times daily, followed by maintenance treatment of up to 3 tablets daily.
This should not be treated as a universal modern dosing recommendation.
Depending on which strength is used, that historical schedule could result in very high daily spironolactone exposure:
Lasilactone 50/20 mg
Four tablets/day would provide:
- Spironolactone: 200 mg/day
- Furosemide: 80 mg/day
Lasilactone 100/20 mg
Four tablets/day would provide:
- Spironolactone: 400 mg/day
- Furosemide: 80 mg/day
Such doses can be appropriate in selected clinical circumstances, particularly certain severe edema or hyperaldosteronism situations, but they are not appropriate as a generic starting regimen for all patients.
Modern dosing should be individualized according to the indication and current product labeling.
Cirrhotic ascites
For cirrhotic ascites, a commonly used clinical starting regimen is:
Spironolactone 100 mg/day + furosemide 40 mg/day
with titration according to response and laboratory results.
This 100:40 mg regimen is widely used because it attempts to maintain potassium balance while achieving effective natriuresis.
Lasilactone 100/20 mg does not reproduce this standard 100/40 ratio; therefore, it should not automatically be assumed that one Lasilactone 100/20 tablet is equivalent to the standard 100/40 mg spironolactone/furosemide regimen.
Similarly, Lasilactone 50/20 mg has a different ratio.
This distinction is clinically important.
13. Method of Preparation
No preparation or reconstitution is required.
Lasilactone is supplied as a ready-to-administer oral film-coated tablet.
The tablet should be swallowed whole with sufficient liquid unless the current product labeling specifically permits another method.
It should not be crushed or altered unless the formulation's current labeling confirms that such manipulation is appropriate.
14. Contraindications
Contraindications should be interpreted from the current approved product labeling.
Important contraindications/avoidance situations include:
Absolute or major contraindications
- Hypersensitivity to spironolactone
- Hypersensitivity to furosemide
- Hypersensitivity to relevant sulfonamide-related compounds where clinically applicable
- Hyperkalemia
- Anuria
- Addison's disease / primary adrenal insufficiency
- Concomitant use with eplerenone
The historical Egyptian leaflet additionally listed:
- Severe renal impairment, including a creatinine-clearance threshold below approximately 30 mL/min
- Sodium depletion/hypovolemia with or without hypotension
- Hepatic coma
- Pregnancy
- Lactation
Some of these should now be understood more precisely as situations requiring avoidance, stabilization, specialist management, or individualized risk-benefit assessment rather than assuming that every statement represents an absolute pharmacological contraindication under every modern regulatory framework.
In particular, renal impairment is not simply an automatic "zero or one" contraindication for all uses of the individual drugs; rather, the risk of hyperkalemia, worsening renal function, and excessive diuresis becomes much greater and dosing must be individualized.
15. Warnings & Precautions
15.1 Hyperkalemia
This is one of the most important safety issues with spironolactone.
Risk is increased by:
- Chronic kidney disease
- Acute kidney injury
- Diabetes mellitus, particularly with renal impairment
- ACE inhibitors
- ARBs
- ARNIs
- Other potassium-retaining drugs
- Potassium supplements
- Potassium-containing salt substitutes
- Trimethoprim-containing medicines
- Other mineralocorticoid receptor antagonists
Serum potassium should be monitored after initiation and dose escalation and periodically thereafter.
Current spironolactone labeling recommends checking serum potassium within approximately one week of initiation or titration, with more frequent monitoring in high-risk patients.
15.2 Hypovolemia and dehydration
Excessive diuresis may produce:
- Dehydration
- Hypotension
- Orthostatic symptoms
- Reduced renal perfusion
- Acute kidney injury
- Circulatory collapse in severe cases
This risk is particularly important in:
- Older adults
- Patients receiving high diuretic doses
- Patients with poor oral intake
- Patients with severe heart failure
- Patients with cirrhosis
- Patients with pre-existing renal impairment
15.3 Electrolyte disturbances
Possible abnormalities include:
- Hyperkalemia
- Hypokalemia
- Hyponatremia
- Hypomagnesemia
- Hypocalcemia
- Hypochloremia
- Metabolic alkalosis
The combination does not eliminate electrolyte disturbances.
Furosemide tends to promote:
- Potassium loss
- Sodium loss
- Magnesium loss
- Calcium loss
Spironolactone tends to promote:
- Potassium retention
- Reduced hydrogen-ion excretion
Therefore, laboratory monitoring remains essential.
15.4 Renal function
Serum creatinine and renal function should be monitored.
A transient increase in serum creatinine can occur with effective diuresis, but a progressive or marked deterioration should prompt clinical reassessment.
If severe progressive renal disease is accompanied by increasing azotemia and oliguria, furosemide therapy may need to be discontinued.
15.5 Cirrhosis and ascites
Patients with cirrhosis are particularly vulnerable to:
- Hypotension
- Acute kidney injury
- Hyponatremia
- Hyperkalemia or hypokalemia
- Hepatic encephalopathy
Rapid alterations in intravascular volume can be dangerous.
Diuretic treatment in significant cirrhotic ascites should therefore be monitored carefully.
15.6 Hepatic encephalopathy
In patients with advanced cirrhosis, excessive diuresis and electrolyte disturbances may precipitate or worsen hepatic encephalopathy.
The historical leaflet used the term "hepatic coma"; current clinical terminology generally emphasizes hepatic encephalopathy.
15.7 Ototoxicity
Furosemide can cause tinnitus and hearing impairment, including potentially irreversible hearing loss.
The risk is particularly associated with:
- High doses
- Rapid intravenous administration
- Severe renal impairment
- Hypoproteinemia
- Concurrent aminoglycosides
- Other ototoxic drugs
Because Lasilactone is an oral product, the classic severe rapid-IV-infusion ototoxicity scenario is less relevant to this formulation, but the intrinsic ototoxic potential of furosemide remains clinically relevant.
15.8 Urinary obstruction
The historical leaflet appropriately warned that diuresis can make symptoms of obstructed urinary outflow clinically apparent or worsen them.
Particular caution is warranted in:
- Prostatic hypertrophy
- Ureteral stenosis
- Other obstructive uropathies
15.9 Hyperuricemia and gout
Furosemide may increase serum uric acid and may precipitate gout attacks in susceptible individuals.
15.10 Diabetes and glucose metabolism
Furosemide may adversely affect glucose metabolism in susceptible patients.
Patients with diabetes should have appropriate monitoring.
15.11 Dyslipidemia
The historical leaflet reports increases in serum cholesterol and triglycerides during furosemide treatment, with a tendency toward normalization during longer treatment.
This is not generally the principal clinical concern with modern furosemide therapy, but the historical observation is retained here for completeness.
15.12 Endocrine effects of spironolactone
Because spironolactone has steroid-hormone-related activity, it may cause:
- Gynecomastia
- Breast tenderness
- Menstrual irregularities
- Reduced libido
- Erectile/sexual dysfunction
- Changes in androgen-dependent hair growth
- Other endocrine effects
Gynecomastia is particularly relevant in men and may be dose-related.
15.13 Voice changes
The historical leaflet reports:
- Hoarseness
- Deepening of the voice in women
- Alteration of voice pitch
and notes that voice changes may occasionally be irreversible.
Although uncommon, this is clinically important in patients whose voice is professionally important, such as singers and professional speakers.
15.14 Hematological effects
Rare hematological abnormalities have been reported, including:
- Thrombocytopenia
- Leukopenia
- Agranulocytosis
- Hemolytic anemia
Unexpected bleeding, fever, severe infection symptoms, or unexplained bruising should prompt medical evaluation.
15.15 Pancreatitis
Rare cases of acute pancreatitis have been reported with furosemide and with diuretic therapy.
Acute severe abdominal pain, particularly with vomiting, requires appropriate clinical evaluation.
16. Drug Interactions
16.1 Potassium supplements
Combination: Spironolactone + potassium supplementation
Risk: Hyperkalemia.
Routine potassium supplementation should not be undertaken without a clear clinical indication and laboratory monitoring.
16.2 Potassium-sparing diuretics
Examples:
- Amiloride
- Triamterene
- Other mineralocorticoid receptor antagonists
Risk: Excessive hyperkalemia.
16.3 ACE inhibitors
Examples:
- Enalapril
- Lisinopril
- Ramipril
ACE inhibitors can increase potassium and may increase the risk of renal dysfunction when combined with diuretics.
16.4 ARBs
Examples:
- Losartan
- Valsartan
- Candesartan
The combination may increase the risk of:
- Hyperkalemia
- Hypotension
- Renal dysfunction
16.5 ARNIs
Sacubitril/valsartan may also increase potassium and renal risk when combined with spironolactone.
16.6 NSAIDs
Examples:
- Ibuprofen
- Diclofenac
- Indomethacin
- Naproxen
NSAIDs can reduce renal prostaglandin synthesis and may:
- Reduce the natriuretic/diuretic response
- Increase the risk of renal dysfunction
- Increase potassium risk in susceptible patients
This interaction is particularly important in patients with cirrhosis, chronic kidney disease, heart failure, or volume depletion.
16.7 Lithium
Furosemide may reduce renal lithium clearance and increase the risk of lithium toxicity.
Concurrent use requires specialist oversight and appropriate lithium-level monitoring; avoidance is preferable when possible.
16.8 Digoxin and cardiac glycosides
Hypokalemia and hypomagnesemia caused by aggressive diuresis can increase susceptibility to cardiac glycoside toxicity.
Conversely, spironolactone can interfere with some laboratory digoxin assays.
16.9 Aminoglycosides
Examples:
- Gentamicin
- Tobramycin
- Amikacin
- Kanamycin
Furosemide can increase the risk of aminoglycoside-associated ototoxicity and potentially nephrotoxicity.
The combination should generally be avoided unless clinically necessary and carefully monitored.
16.10 Cisplatin
Furosemide can increase the risk of ototoxicity and nephrotoxicity in conjunction with cisplatin.
16.11 Corticosteroids
Examples:
- Prednisolone
- Dexamethasone
- Hydrocortisone
Corticosteroids can increase potassium loss when used with furosemide.
16.12 Laxative abuse
Prolonged or excessive laxative use can contribute to potassium depletion and may aggravate electrolyte disturbances caused by furosemide.
16.13 Salicylates
The historical leaflet states that salicylates may attenuate the effect of spironolactone and that furosemide can interact with salicylates.
Clinically significant interaction risk depends on dose and patient factors.
16.14 Carbenoxolone
The historical leaflet states that spironolactone may reduce the effect of carbenoxolone.
Carbenoxolone is now rarely encountered in routine practice in many countries.
16.15 Antihypertensive drugs
The hypotensive effect of other antihypertensives may be potentiated.
This includes:
- ACE inhibitors
- ARBs
- Beta-blockers
- Other antihypertensive agents
Blood pressure and symptoms should therefore be monitored.
17. Side Effects
Common or clinically important adverse effects
Related to diuresis
- Increased urination
- Thirst
- Dry mouth
- Dehydration
- Dizziness
- Weakness
- Hypotension
- Orthostatic symptoms
- Muscle cramps
Electrolyte/metabolic
- Hyperkalemia
- Hypokalemia
- Hyponatremia
- Hypomagnesemia
- Hypocalcemia
- Metabolic alkalosis
- Hyperuricemia
- Possible glucose abnormalities
Gastrointestinal
- Nausea
- Vomiting
- Diarrhea
- Abdominal discomfort
Spironolactone-related endocrine effects
- Gynecomastia
- Breast tenderness
- Menstrual irregularities
- Sexual dysfunction
- Reduced libido
- Hirsutism or other hormonal effects
- Voice changes, rarely
Neurological
- Dizziness
- Headache
- Drowsiness
- Confusion, particularly with excessive diuresis or severe electrolyte disturbance
Renal
- Increased serum creatinine
- Worsening renal function
- Acute kidney injury in susceptible patients
Hematological
Rarely:
- Thrombocytopenia
- Leukopenia
- Agranulocytosis
- Hemolytic anemia
Dermatological/allergic
Possible:
- Rash
- Photosensitivity
- Vasculitis
- Fever
- Hypersensitivity reactions
- Interstitial nephritis as part of a hypersensitivity reaction
Rare severe cutaneous adverse reactions have also been reported with furosemide-containing therapy.
Auditory
- Tinnitus
- Hearing impairment
- Rarely permanent hearing loss
Serious adverse reactions requiring urgent attention
- Severe weakness
- Palpitations or irregular heartbeat
- Syncope
- Severe hypotension
- Marked reduction in urine output
- Severe dehydration
- Confusion
- Severe abdominal pain
- Significant bleeding/bruising
- Severe allergic reaction
- Sudden hearing loss
18. Use in Special Populations
18.1 Pregnancy
Lasilactone should generally not be used during pregnancy unless there is a clear specialist indication and the expected maternal benefit outweighs potential fetal risk.
Spironolactone has antiandrogenic activity and animal data raise concern about effects on male fetal sexual differentiation.
The old leaflet listed pregnancy as a contraindication; current regulatory language may differ between jurisdictions, but routine use during pregnancy should be avoided unless specifically justified.
Furosemide should also not be used routinely merely for physiological edema of pregnancy.
18.2 Breastfeeding
The historical Egyptian leaflet instructed that breastfeeding should be stopped if Lasilactone was required.
Current assessment is more nuanced for the individual components, but because:
- Spironolactone has an active metabolite detectable in breast milk
- Furosemide can produce substantial diuresis
- High-dose diuretic therapy may potentially reduce milk production
the combination should be used during lactation only when clinically justified and under medical supervision.
The current local product information should be consulted for the exact Egyptian recommendation.
18.3 Pediatric patients
Routine use of this fixed-dose adult combination in children should not be assumed to be appropriate.
Pediatric furosemide and spironolactone dosing is generally weight-, indication-, renal-function-, and electrolyte-dependent.
A fixed-dose Lasilactone tablet may be unsuitable when precise pediatric dose adjustment is required.
18.4 Older adults
Older patients are more vulnerable to:
- Dehydration
- Orthostatic hypotension
- Electrolyte disturbances
- Acute kidney injury
- Falls
- Drug interactions
Treatment should therefore generally start cautiously with close monitoring.
18.5 Renal impairment
Renal impairment substantially increases the clinical complexity of treatment.
Potential problems include:
- Reduced effective diuretic response in advanced renal disease
- Hyperkalemia from spironolactone
- Worsening renal function
- Volume depletion
Serum creatinine/eGFR and potassium should be assessed before treatment and monitored during therapy.
The historical Egyptian leaflet used specific creatinine and creatinine-clearance thresholds. These should not be applied blindly as universal modern cutoffs because current prescribing decisions are based on the indication, degree of renal impairment, potassium concentration, and concomitant medications.
18.6 Hepatic impairment
In cirrhosis, spironolactone is particularly useful because secondary hyperaldosteronism is an important contributor to sodium retention.
However, patients with advanced liver disease are also particularly vulnerable to:
- Hypotension
- Hyponatremia
- Acute kidney injury
- Hyperkalemia
- Hepatic encephalopathy
Diuretic therapy therefore requires careful clinical and laboratory monitoring.
19. Monitoring Parameters
Before and during therapy, clinically relevant monitoring may include:
Baseline
- Blood pressure
- Weight
- Volume status
- Serum potassium
- Serum sodium
- Serum creatinine/eGFR
- Urea/BUN
- Magnesium when clinically indicated
- Uric acid when clinically indicated
- Glucose in susceptible patients
Follow-up
- Weight and edema/ascites
- Blood pressure
- Serum potassium
- Serum sodium
- Renal function
- Symptoms of dehydration
- Symptoms of hyperkalemia
- Urine output when clinically relevant
In high-risk patients, laboratory monitoring should be performed more frequently.
20. Storage Conditions
The exact current Egyptian storage instructions should be checked against the current carton/leaflet.
Historical Lasilactone product information for the 50/20 mg formulation states:
- Store below 25°C
- Keep the blister strip in the outer carton to protect from light
- Keep out of the sight and reach of children
Do not use the product after the expiry date printed on the packaging.
Do not use tablets if the packaging is damaged or the product has undergone obvious physical deterioration.
21. Additional Sections
21.1 Important distinction between the two Egyptian strengths
The two products are not interchangeable tablet-for-tablet.
One Lasilactone 50/20 tablet:
Spironolactone 50 mg + furosemide 20 mg
One Lasilactone 100/20 tablet:
Spironolactone 100 mg + furosemide 20 mg
Therefore, changing from one strength to the other changes the spironolactone dose by 100% while leaving the furosemide dose unchanged.
21.2 Why potassium monitoring remains necessary
A common misconception is that combining spironolactone with furosemide automatically prevents potassium abnormalities.
It does not.
The final potassium concentration depends on:
- Relative doses
- Renal function
- Dietary potassium
- Aldosterone activity
- ACE inhibitor/ARB/ARNI therapy
- Diabetes
- Other medications
- Degree of diuresis
Therefore, the combination should not be considered "self-balancing" with respect to potassium.
21.3 Standard cirrhotic ascites ratio versus Lasilactone ratios
A frequently used cirrhotic ascites regimen is:
Spironolactone 100 mg : furosemide 40 mg
Lasilactone 100/20 provides:
Spironolactone 100 mg : furosemide 20 mg
Therefore, it contains half the furosemide dose of the commonly used 100/40 regimen.
Lasilactone 50/20 provides:
Spironolactone 50 mg : furosemide 20 mg
Thus, the physician should calculate the actual doses of both components rather than prescribing by brand strength alone.
21.4 Historical leaflet versus current evidence
Several statements in the supplied historical leaflet are clearly older in style or overly broad by modern standards.
Examples include:
- A blanket pregnancy/lactation contraindication
- Fixed creatinine thresholds presented as universal contraindications
- "Thrombophilia" listed among adverse effects of excessive diuresis
- Very broad historical dosing instructions
- The older 10-tablet presentation
- Older terminology such as "hepatic coma"
These statements have therefore been retained for historical completeness where relevant, but modern clinical interpretation has been provided alongside them.
21.5 Driving and operating machinery
The old leaflet states that the ability to drive, cross the road safely, or operate machinery may be impaired in some patients, particularly:
- At initiation of therapy
- When changing from another medication
- When alcohol is consumed
The principal practical concern is dizziness, hypotension, weakness, or altered alertness caused by diuresis or electrolyte disturbances.
Patients experiencing these effects should avoid driving or operating machinery until symptoms resolve.
21.6 Overdose
Overdose may produce excessive diuresis and potentially severe:
- Hypovolemia
- Hypotension
- Electrolyte abnormalities
- Hyperkalemia or hypokalemia
- Hyponatremia
- Renal dysfunction
- Cardiac arrhythmias
Management is supportive and should focus on:
- Volume status
- Electrolytes
- Renal function
- Blood pressure
- Cardiac monitoring when clinically indicated
Severe overdose requires urgent medical assessment.
22. Frequently Asked Questions (FAQ)
Q1. What is Lasilactone used for?
It is a combination diuretic containing spironolactone and furosemide, used clinically for selected patients with edema or fluid retention, including conditions such as cirrhosis-associated ascites and heart-failure-associated edema.
Q2. Is Lasilactone a potassium-sparing diuretic?
Partly.
Spironolactone is potassium-sparing, while furosemide is potassium-wasting.
The combination therefore has mixed effects on potassium, and serum potassium still needs monitoring.
Q3. What is the difference between Lasilactone 50/20 and 100/20?
The furosemide dose is the same in both:
20 mg furosemide
The difference is the spironolactone dose:
- 50/20 = 50 mg spironolactone
- 100/20 = 100 mg spironolactone
Q4. Can Lasilactone cause high potassium?
Yes.
This is mainly due to spironolactone and is particularly important in patients with renal impairment or those taking ACE inhibitors, ARBs, ARNIs, potassium supplements, or other potassium-raising drugs.
Q5. Can Lasilactone cause low potassium?
Yes.
Furosemide promotes potassium loss. Although spironolactone counteracts this tendency, hypokalemia can still occur depending on the dose ratio and clinical circumstances.
Q6. Can Lasilactone damage the kidneys?
It can contribute to worsening renal function, particularly when excessive diuresis causes volume depletion or when combined with other nephrotoxic or renal-hemodynamic drugs.
It is not accurate to say that Lasilactone inevitably "damages the kidneys"; the risk depends strongly on the patient's clinical condition and monitoring.
Q7. Should Lasilactone be taken at night?
Usually it is preferable to take it earlier in the day because furosemide increases urine production.
The historical leaflet specifically recommends breakfast or lunch rather than evening administration.
Q8. Can Lasilactone be used for simple leg swelling without a diagnosis?
It should not be used simply as a self-treatment for unexplained edema.
Leg edema can result from:
- Heart failure
- Venous insufficiency
- Renal disease
- Liver disease
- Medication effects
- Lymphedema
- Hypoalbuminemia
- Deep-vein thrombosis
- Other conditions
The cause should be established before long-term diuretic therapy.
Q9. Can Lasilactone be used for ascites due to cirrhosis?
Yes, spironolactone plus furosemide is a standard diuretic strategy for appropriate patients with cirrhotic ascites.
However, dosing must be individualized, and patients require monitoring of renal function, sodium, potassium, body weight, blood pressure, and clinical response.
Q10. Is Lasilactone 100/20 equivalent to spironolactone 100 mg + furosemide 40 mg?
No.
Lasilactone 100/20 contains:
- Spironolactone 100 mg
- Furosemide 20 mg
It is therefore not equivalent to 100 mg spironolactone + 40 mg furosemide.
Q11. Can Lasilactone be taken with ibuprofen or diclofenac?
This combination should be used cautiously.
NSAIDs may reduce the diuretic response and increase the risk of renal dysfunction and electrolyte disturbances, particularly in patients with heart failure, cirrhosis, dehydration, or chronic kidney disease.
Q12. Can Lasilactone be taken with an ACE inhibitor?
It can be used in selected patients, but the combination can increase the risk of:
- Hyperkalemia
- Hypotension
- Renal dysfunction
Close monitoring is important.
Q13. Can Lasilactone cause gynecomastia?
Yes.
Spironolactone can cause gynecomastia and breast tenderness, particularly with prolonged treatment and higher doses.
Q14. Can Lasilactone affect menstruation?
Yes.
Spironolactone can cause menstrual irregularities and other hormonal effects.
Q15. Can Lasilactone cause hearing loss?
Furosemide can cause ototoxicity, particularly at high doses, with rapid intravenous administration, severe renal impairment, or concomitant ototoxic medications such as aminoglycosides.
Severe ototoxicity is much more strongly associated with high-dose parenteral therapy than routine oral therapy.
Q16. Is Lasilactone safe during pregnancy?
It should generally be avoided unless a specialist determines that the benefits clearly outweigh the risks.
Spironolactone's antiandrogenic activity is particularly relevant to fetal development.
Q17. Can Lasilactone be used while breastfeeding?
The decision should be individualized and based on the current local product information and clinical necessity.
The historical Egyptian leaflet advised stopping breastfeeding if Lasilactone was required.
Q18. Is the old Lasilactone dosage in the supplied leaflet still valid?
The historical dosing information should not be copied directly into modern prescribing practice without clinical assessment.
The old leaflet's maximum schedules can produce relatively high total daily doses, particularly with the 100/20 mg strength.
Modern treatment should be individualized according to indication, renal function, potassium, blood pressure, volume status, and response.
23. References
-
Sanofi / Lasilactone historical product information supplied by the user, including the Egyptian leaflet stating the composition, indications, warnings, interactions, dosage, administration, presentation, and local production information.
-
Current Egyptian-market pharmacy listings for Lasilactone 50/20 mg and 100/20 mg, confirming the currently listed Egyptian presentations and Sanofi manufacturer information.
-
U.S. FDA — Aldactone (spironolactone) Prescribing Information, revised 2025, for current pharmacokinetic information, contraindications, hyperkalemia warnings, renal considerations, and adverse effects.
-
DailyMed — Spironolactone tablets, current prescribing information, for contraindications, dosing principles, hyperkalemia monitoring, and renal/volume precautions.
-
DailyMed — Furosemide tablets, current prescribing information, for indications, contraindications, pharmacokinetics, electrolyte depletion, renal effects, and ototoxicity.
-
FDA — Furosemide prescribing information, including drug-interaction information concerning aminoglycosides, lithium, salicylates, cisplatin, and other interacting medicines.
-
AASLD educational guidance on cirrhotic ascites, including the commonly used spironolactone 100 mg/furosemide 40 mg starting regimen and the clinical rationale for combined therapy.
-
AASLD — Outpatient Management of Cirrhosis, discussing sodium restriction, spironolactone/furosemide therapy, NSAID/ACE inhibitor/ARB considerations, and management of refractory ascites.
-
EMA — Furosemide/spironolactone regulatory documentation, documenting internationally authorized products containing the same active ingredients and historical Sanofi-affiliated marketing authorization holders.
-
Sanofi Lasilactone product information from other regulated markets, used only to supplement formulation/pharmacology information where Egyptian current regulatory information was not publicly accessible.
24. Overall Clinical Assessment
Lasilactone is a rational fixed-dose diuretic combination of spironolactone and furosemide, particularly useful when both aldosterone-mediated sodium retention and substantial natriuresis need to be addressed.
Its major clinical advantages are:
- Complementary mechanisms of action
- Strong natriuretic/diuretic effect
- Usefulness in edema and ascites
- Aldosterone antagonism
- Potential reduction of furosemide-associated potassium loss
Its major limitations and safety concerns are:
- Hyperkalemia
- Hypokalemia
- Hyponatremia
- Dehydration
- Hypotension
- Renal dysfunction
- Drug interactions
- Spironolactone-related endocrine adverse effects
- Potential furosemide-related ototoxicity
The 50/20 mg and 100/20 mg formulations should be prescribed according to the actual doses of each component rather than treating them as interchangeable "diuretic tablets."
For cirrhotic ascites in particular, the commonly used 100 mg spironolactone + 40 mg furosemide regimen should not be confused with Lasilactone 100/20 mg, which contains only 20 mg of furosemide.
The historical Egyptian leaflet remains useful for understanding the product's earlier labeling, but its older dosing instructions, contraindication wording, packaging information, and terminology should not be assumed to represent the current regulatory standard.
In clinical practice, the current Egyptian approved package leaflet and the patient's renal function, potassium level, blood pressure, volume status, and underlying indication should determine the final regimen.